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Abstract
The consumption of contaminated shellfish with okadaic acid (OA) group of toxins leads to diarrhoeic shellfish poisoning 
(DSP) characterized by a set of symptoms including nausea, vomiting and diarrhoea. These phycotoxins are Ser/Thr phos-
phatase inhibitors, which produce hyperphosphorylation in cellular proteins. However, this inhibition does not fully explain 
the symptomatology reported and other targets could be relevant to the toxicity. Previous studies have indicated a feasible 
involvement of the nervous system. We performed a set of in vivo approaches to elucidate whether neuropeptide Y (NPY), 
Peptide YY (PYY) or serotonin (5-HT) was implicated in the early OA-induced diarrhoea. Fasted Swiss female mice were 
administered NPY, PYY(3–36) or cyproheptadine intraperitoneal prior to oral OA treatment (250 µg/kg). A non-significant 
delay in diarrhoea onset was observed for NPY (107 µg/kg) and PYY(3–36) (1 mg/kg) pre-treatment. On the contrary, the 
serotonin antagonist cyproheptadine was able to block (10 mg/kg) or delay (0.1 and 1 mg/kg) diarrhoea onset suggesting a 
role of 5-HT. This is the first report of the possible involvement of serotonin in OA-induced poisoning.
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Introduction
Okadaic acid (OA) group of toxins comprise polyether fatty 
acids synthetized by dinoflagellates of the genera Prorocen-
trum and Dinophysis. Bivalves may accumulate the toxins 
following the consumption of this toxic phytoplankton. 
Therefore, OA and related compounds enter the food chain 
reaching humans through toxin-containing seafood inges-
tion causing diarrhoeic shellfish poisoning (DSP) (Yasumoto 
et al. 1978). DSP can be developed fast, between 30 min 
and a few hours afterwards. Symptomatology includes nau-
sea, vomiting, diarrhoea and abdominal pain, achieving full 
recovery after 3 days (Yasumoto et al. 1978; EFSA 2008). 
Exposure to DSP has been frequently reported in various 
countries (Young et al. 2019; Vale 2020), representing the 
primary cause of bans on the harvesting of aquaculture in 
Japan and Europe (Reguera et al. 2014).
Previous studies have revealed that OA inhibits serine/
threonine protein phosphatases (PPs) 1, 2A, 4, 5 and 6 activ-
ity (Bialojan and Takai 1988; Brewis et al. 1993; Chen et al. 
1994; Prickett and Brautigan 2006). PPs remove a phos-
phate group from the phosphorylated amino acid residue 
of a wide variety of proteins (Yadav et al. 2017), meaning 
disturbance in their activity can modify downstream cel-
lular pathways. OA in vitro has been described to induce 
cytoskeleton reorganization (Espina et al. 2010; Opsahl et al. 
2013; Louzao et al. 2015), cell death (Dietrich et al. 2020) 
and cell cycle alteration (Feng et al. 2018). However, during 
the last decade, it has been discussed whether OA-exerted 
effects are fully explained by its PP inhibition (Espina et al. 
2010; Munday 2013). 
Diarrhoea is defined as reduced stool consistency, 
increased water content and number of evacuations. A 
wide array of causes and pathophysiological mechanisms 
have been proposed for both infectious and non-infectious 
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diarrhoea (Thiagarajah et al. 2015; Anand et al. 2016; 
Camilleri et al. 2017). A considerable number of those 
mechanisms involve neuronal activation of the Enteric 
Nervous System (ENS). The ENS together with parasym-
pathetic and sympathetic innervation throughout the gas-
trointestinal tract coordinate and regulate essential func-
tions regarding pancreatic secretion, gut motility, fluid 
secretion and nutrient absorption among others (Li et al. 
2000; Hu and Spencer 2018). Within components of the 
ENS some members of the Neuropeptide Y (NPY) family 
have been closely related to functions such as fluid absorp-
tion and gastric emptying (Saria and Beubler 1985; Wang 
et al. 2010). These 36-aa peptides’ location include neu-
ral and endocrine components (Ekblad and Sundler 2002; 
Mongardi Fantaguzzi et al. 2009). For instance, NPY is 
expressed in different regions of the brain, but also in 
sympathetic neurons and in the ENS (e.g., secretomotor 
neurons) (Cox 2007; Mongardi Fantaguzzi et al. 2009). 
On the contrary, enteroendocrine L cells are the mayor 
contributors of Peptide YY (PYY) in the body, though it 
has been likewise detected in myenteric neurons and in 
some brain areas (Ekblad and Sundler 2002; Morimoto 
et al. 2008). In vitro, the DSP toxin OA downregulated 
NPY content and release of SH-SY5Y neuroblastoma cell 
line (Valdiglesias et al. 2012; Louzao et al. 2015).
Another key signalling molecule in the gut is seroto-
nin (5-HT), a bioamine mainly expressed along the diges-
tive tract (Erspamer and Testini 1959; Erspamer 1966; 
Savelieva et al. 2008; Mawe and Hoffman 2013), whose 
physiological functions comprise intestine fluid secretion 
and motility (El-Salhy et al. 2013; Mawe and Hoffman 
2013; Coates et al. 2017; Camilleri et al. 2017; Hu and 
Spencer 2018). 5-HT is present in serotoninergic enteric 
neurons (Okamoto et al. 2014), though enterochromaffin 
cells (ECCs) are its major producers which are scattered 
distributed along the epithelia (Sjolund et al. 1983). ECCs 
act as chemosensors (Braun et al. 2007; Lund et al. 2018) 
and mechanosensors (Fujimiya et al. 1997; Alcaino et al. 
2018), triggering a response in the underlying nerve ter-
minals and the surrounding cells via neurotransmitters’ or 
hormones’ signalling (Bertrand et al. 2000; Reynaud et al. 
2016; Fazio Coles et al. 2020).
Gathering the variety of pathophysiologic mechanisms 
resulting in diarrhoea and the important role of the ENS, 
we studied if OA-caused diarrhoea involves alteration of 
intestinal hormones (PYY) and/or neurotransmitters (5-HT 
and NPY). To elucidate this premise, we firstly performed 
an in vivo approach to determinate the dose–response of 
OA doses on diarrhoea outcome. Second, we assessed the 
effect of exogenous NPY or PYY(3–36) on OA-induced 
diarrhoea. Furthermore, we evaluated 5-HT implication 
in DSP in mice using the 5-HT1 and 5-HT2 antagonist 
cyproheptadine (CPH) prior to OA treatment.
Materials and methods
Animal model
Mouse bioassay had been an accepted method for marine 
biotoxins detection, though nowadays has been replaced by 
analytical methods on behalf of NC3R’s principles (Union 
2011). Based on the Organization for Economic Cooperation 
and Development guidelines for acute oral toxicity studies, 
we decided to use female mice as an animal model (OECD/
OCDE 2002). One-month-old Swiss female mice weighing 
between 18 and 22 g from the colonies of the University of 
Santiago de Compostela were employed for all the experi-
ments described. They were kept in controlled conditions of 
temperature (23 ± 2 °C), humidity (60–70%) and light/dark 
cycles (12 h/ 12 h). Mice were placed individually on meta-
bolic cages and fasted overnight with access to 5% glucose 
serum. Animals were randomly assigned to each treatment. 
Mice received the toxin by oral gavage at 9 a.m. (10 mL/kg 
body weight), moment at which food and drink were pro-
vided ad libitum. When any pre-treatment was studied, it was 
given by intraperitoneal injection (1% body weight) prior to 
the toxin. Note that the assays described hereafter were pre-
ceded by these conditions. At the end of each experiment, 
euthanasia by  CO2 inhalation was conducted. All animal 
procedures were carried out in conformity to the European 
(EU directive 2010/63/EU), the Spanish legislation (Real 
Decreto 53/2013, Decreto 296/2008) and to the principles 
approved by the Institutional Animal Care Committee of the 
University of Santiago de Compostela under the procedure 
Code: 01/17/LU-002 (approved on 22 September 2017).
Materials
Okadaic acid employed in this study was kindly provided 
by the National Research Institute of Fisheries Science 
(NRIFS) from the Fisheries Research and Education Agency 
(Yokohama, Japan). OA isolated from toxic dinoflagellate 
Prorocentrum lima (Suzuki et al. 2014) was quantified by 
PULCON method (Watanabe et al. 2016) on the quantita-
tive NMR with an external standard. Purities (purity > 95%) 
were also confirmed by the NMR spectroscopy. Neuropep-
tide Y and Peptide YY(3–36) were purchased from TOCRIS, 
cyproheptadine hydrochloride sesquihydrate from Sigma-
Aldrich. All chemicals employed were analytical grade from 
Sigma-Aldrich Quimica S.A. (Madrid, Spain).
Dose–response of okadaic acid on diarrhoea
OA was previously reconstituted with ethanol. For adminis-
tration, OA doses were prepared by serial dilutions in 0.9% 
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saline solution. OA was given by oral gavage at 10, 50, 100, 
250 and 400 µg/kg doses. Control mice received the vehicle 
alone. Diarrhoea onset time and diarrhoea score were regis-
tered along with the symptoms presented at 1, 3, 6, 9, 12 and 
24 h. Anatomopathological examination took place when the 
necropsy was performed. Small and large intestines were 
removed and stored at − 20 °C.
Pre‑treatment in vivo studies at 6 h
NPY was previously reconstituted with milliQ water. Doses 
of 550 µg/kg OA and 107 µg/kg NPY were prepared by 
dilution of each compound in physiological solution. Four 
treatment groups were set: (i) control, (ii) NPY, (iii) OA 
and (iv) NPY plus OA. Each group was performed in dupli-
cate. In this last case, intraperitoneal injection of NPY was 
performed 15 min prior to OA administration by oral gav-
age. The time of diarrhoea outbreak, diarrhoea score and 
symptomatology were registered and stools collected at 1, 3 
and 6 h of treatment. At the end of the experiment, animals 
were subjected to necropsy. Small and large intestines were 
sampled and kept at − 20 °C.
A similar approach was performed for PYY(3–36) pre-
treatment studies. PYY(3–36) was also reconstituted with 
milliQ water. The peptide was diluted in physiological solu-
tion to reach 1 mg/kg PYY(3–36). Mice were split into four 
groups comprising control, PYY(3–36), OA and PYY(3–36) 
plus OA. In this last group, PYY(3–36) was given by intra-
peritoneal injection 15 min before oral administration of 
550 µg/kg OA. Same performance and data as in the previ-
ous experiment were obtained, ending the experiment at 6 h 
post-toxin administration.
CPH pre-treatment approach was in line with the previous 
ones. CPH was first reconstituted with ethanol. CPH was 
diluted in physiological solution to prepare the dose 3 mg/
kg. Different sets of animals were given vehicles, CPH or 
OA each alone or CPH plus OA. Mice were first injected 
CPH intraperitoneally 30 min prior to 250 µg/kg OA by oral 
gavage. Same data as in the previous approaches were also 
collected.
NPY or PYY(3–36) pre‑treatment of mice in 2 h 
experiments
Preparation of treatments and administration were performed 
as described in the preceding assessment. The peptides were 
each diluted in physiological solution to obtain 107 µg/kg 
NPY and 1 mg/kg PYY(3–36). NPY or PYY(3–36) was 
given intraperitoneal 15 min before oral administration of 
250 µg/kg OA. During the following 2 h, the same data as 
detailed in the above experiment were obtained.
Dose–response of cyproheptadine in vivo at 2 h
Doses of 0.1, 1, 3 and 10 mg/kg CPH were tested as a pre-
treatment to 250 µg/kg OA for 2 h. The experimental devel-
opment was as detailed above. Dosages were diluted in 
physiological solution. OA was given by oral gavage 30 min 
after CPH dose was injected via intraperitoneal. Mice were 
observed, stools were collected, diarrhoea score and time of 
onset were measured 2 h of treatment. Then necropsy was 
performed and the gut was removed and stored at −20 °C.
Short‑time exposure CPH dose–response
CPH and OA doses were prepared as described in previous 
sections. In this case, animals were split in six groups: (i) 
control, (ii) CPH, (iii) OA, (iv) 0.1 mg/kg CPH plus OA, (v) 
1 mg/kg CPH plus OA and (vi) 6 mg/kg CPH plus OA. CPH 
was given via intraperitoneal 30 min before administering 
250 µg/kg OA by oral gavage. Mice receiving the toxin alone 
were first treated, the time of diarrhoea onset was set as the 
end of the experiment for the remaining treatments. Same 
performance and data as in the previous experiment were 
obtained, but for 30 min post-toxin administration.
Diarrhoea score
To assess the differences in terms of how severe the diar-
rhoea was, we designed a scoring system (Table 1), meaning 
0 normal faeces; 1 soft faeces; 2 shapeless soft faeces; 3 
watery diarrhoea; 4 having for more than once diarrhoea. To 
be considered a different time of diarrhoea, it was required 
to be at least 20 min past the last defecation.
Neuromodulators’ detection
Small intestine (ileum) and large intestine (proximal colon) 
were first extracted. Samples were cleansed in ice-cold PBS 
and weighted immediately afterwards. PBS was added (1:9 
w/v) and tissues were homogenized and sonicated. Finally, 
they were centrifuged for 5 min at 10,000×g at 4 °C and 
Table 1  Diarrhoea scoring 
system criteria




2 Shapeless soft faeces
3 Watery diarrhoea
4 Watery diarrhoea 
repeatedly
(taking into account 
20 min between each 
time)
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stored at − 20 °C. When required, extracts were diluted for 
the compounds’ concentration to fall within the linear range 
of the standard solutions. In all cases, absorbance was meas-
ured in a Multi-mode Microplate Reader Synergy 4 (Biotek).
NPY was measured in samples from OA dose–response 
at 24 h and from 6 h NPY pre-treatment studies. Enzyme-
linked Immunosorbent Assay (ELISA) Kit for Neuropep-
tide Y from Cloud Clone Corp. was employed. The range of 
detection was 2.47–200 pg/mL and absorbance was meas-
ured at 450 nm.
PYY was analysed in mice intestines from OA 
dose–response at 24 h and from 6 h PYY(3–36) pre-treat-
ment experiments. ELISA Kit for Peptide YY (Cloud-Clone 
Corp.) was used. The detection range was 12.35–1000 pg/
mL and absorbance was read at 450 nm.
5-HT was determined in samples stored from CPH pre-
treatment (6 h), dose–response of CPH (2 h) and short time 
exposure CPH dose–response experiments. The Serotonin 
ELISA kit from Enzo Life Sciences was used for 5-HT 
detection. The range of detection was 0.49–500 ng/mL and 
absorbance was read at 405 nm.
Statistical analysis
Graphpad Prism and RStudio were employed to perform 
the statistical analyses. First, the distribution and homosce-
dasticity of the data set were tested. If it followed a normal 
distribution, t test was performed to compare two treatments 
or one-way ANOVA plus Bonferroni multiple comparison 
test in the case more groups were analysed. Conversely, 
under no normal distribution of data, Mann–Whitney test 
or Kruskal–Wallis test followed by Bonferroni multiple 
comparison test was conducted. The significance threshold 
was set at P < 0.05.
Results
Dose–response of okadaic acid
To determine at which concentration OA is able to trigger 
diarrhoea, several doses of the toxin (10, 50, 100, 250 and 
400 µg/kg) were administered to mice that were observed 
for 24 h. During the experiment, the symptomatology was 
monitored in detail at 1, 3, 6, 9, 12 and 24 h of OA treat-
ment. No symptoms were detected in 10 µg/kg treated mice 
throughout the experiment. In the case of 50 µg/kg dose, 
these animals did not present any symptoms, but one mouse 
alone had soft faeces at 12 h, being normal at 24 h. Treat-
ments of 100, 250 and 400 µg/kg induced squint-eyes, pilo-
erection, spasms, cyanosis and even death for the highest 
dose (Table 2). This approach allowed to register the time at 
which mice recovered, i.e., had no symptoms. Clinical signs 
were noted at 1 h for 100 µg/kg OA treatment, being absent 
at 3 h. None of the reported symptoms were identified at 9 h 
for 250 µg/kg OA. Finally, no mice that received 400 µg/kg 
OA reached the 24 h of treatment.
Variations in body weight after 24 h of OA treatment 
were measured, as well as food and water consumption dur-
ing the experiment (Fig. 1a). Both body weight variation and 
food intake display a similar pattern.
At the end of the experiment, mice were subjected to 
necroscopic analysis, focusing on anatomopathological eval-
uation of the gastrointestinal tract (Fig. 1b). While 10, 50 
and 100 µg/kg OA examination revealed no differences with 
control, 250 µg/kg dose was featured by a swollen stomach 
and fluid accumulation in the small intestine. In the case of 
400 µg/kg OA-treated mice, swollen stomach accompanied 
by moderate to strong fluid accumulation in the small intes-
tine were observed for all animals.
Neuropeptides like NPY and PYY are involved in the 
regulation of nutrients absorption and exert a protective role 
(Moriya et al. 2010; Tough et al. 2011). Thus, we aimed 
to elucidate how OA affects NPY and PYY along the gut 
in vivo after 24 h treatments. OA reduces NPY in the small 
Table 2  Symptomatology of 
24 h OA-treated animals (%)
Symptoms Control OA (µg/kg)
10 50 100 250 400
Apathy 0 0 0 33.3 100 50
Piloerection 0 0 0 33.3 66.7 50
Cyanosis 0 0 0 0 0 50
Spasms 0 0 0 33.3 66.7 50
On hind legs 0 0 0 66.7 33.3 0
Squint-eyes 0 0 0 66.7 66.7 50
Diarrhoea 0 0 0 100 100 100
Mortality 0 0 0 0 0 100
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intestine and in large intestine (Fig. 1c). Only 250 µg/kg 
OA treatment decreases PYY in small intestine while large 
intestine’s PYY is not affected by OA at any of the given 
doses at 24 h (Fig. 1d).
The evaluation of clinical signs was focused on diar-
rhoea (percent of mice with this symptom, diarrhoea onset 
time and diarrhoea score). To assess the severity of diar-
rhoea, faeces from each mouse were scored as described 
above (Table 1). Based on diarrhoea score criteria, there is 
a dose-dependent increase up to the maximal punctuation 
(Fig. 1e). Control, 10 µg/kg and 50 µg/kg OA had normal 
faeces, except for one mouse that received the latter dose. 
Then the lowest dose tested for developing diarrhoea was 
100 µg/kg, with several defecations. Since neither control, 
10 nor 50 µg/kg treated mice had diarrhoea, no onset is rep-
resented regarding these treatments (Fig. 1f).
To further assure diarrhoea in the following approaches, 
we also included the dose: 550 µg/kg OA (Fig. 1f). We found 
no significant differences in diarrhoea onset between any of 
the OA doses that triggers the symptom, showing an all-or-
none response.
NPY effect on OA poisoning in 6 h experiments
Based on how OA affected in vitro NPY expression in 
addition to the pro-absorptive role of the neuropeptide, we 
designed a 6 h experiment in which mice were intraperito-
neally administered NPY prior to OA treatment. Due to the 
lack of differences between doses in diarrhoea onset (Fig. 1f) 
along with the evaluation of a dose closer to the previously 
described oral  LD50 for OA (760 µg/kg) (Abal et al. 2018), 
we considered 550 µg/kg to be suitable to perform this 
assessment. The time of the experiment, 6 h, was selected 
to assure not just the inhibition of diarrhoea detection, but 
any delay in diarrhoea onset. Symptomatology of the ani-
mals was recorded during the experiment (Table S1). Most 
animals exhibited a variety of symptoms such as piloerec-
tion and squint-eyes. Symptoms were still observed in mice 
treated with OA alone or NPY-OA at the end of the experi-
ment. It should be remarked the fact that all mice treated 
with the toxin or with the combination of both, OA and NPY 
(NPY-OA), developed diarrhoea.
Body weight variations (Fig. S1a), food (Fig. S1b) and 
water intake (Fig. S1c) were measured. Necropsy of all 
animals revealed that the toxin induced fluid accumulation 
along the small intestine, being modestly improved by NPY 
(Fig. S1d).
The type of diarrhoea was evaluated with the diarrhoea 
score (Fig. 2a). Pre-treatment with NPY did not modify 
OA-induced diarrhoea nor supressed it (Fig. 2a). Diarrhoea 
onset time displays a short, non-significant, delay with NPY 
pre-treatment (OA 33 ± 3.4 min; NPY-OA 43 ± 4.9 min) 
(Fig. 2b).
NPY was measured in the intestine of these animals 6 h 
after toxin administration (Fig.  2c, d). OA reduces NPY 
concentration in the small intestine; meanwhile, in NPY-
OA-treated animals’ NPY resembles control concentration 
(Fig. 2c). Conversely, the same treatment seems to induce a 
modest rise of NPY in the large bowel (Fig. 2d).
PYY(3–36) effect on OA poisoning in 6 h 
experiments
The enteric nervous system plays a vital role in the response 
to various gastrointestinal stimuli. The peptides of this nerv-
ous system regulate gastrointestinal movement, secretion, 
absorption and other complex functions through endocrine, 
paracrine and neuronal actions. Both NPY and Peptide YY 
are important enteric peptides. The observation of a soft effect 
of NPY over OA intoxication led us to study PYY.  Y2 recep-
tors are not only in nerve terminals around myenteric neu-
rons, but also in mucosa and muscle layers and its agonist 
PYY(3–36) has additionally been related to a clear anti-diar-
rhetic effect (Moriya et al. 2010; Tough et al. 2011). Thus, we 
aimed to check whether this agonist had the ability to relieve 
OA-induced diarrhoea. PYY(3–36) (1 mg/kg) was adminis-
tered prior to OA (550 µg/kg) was given. Symptomatology 
was monitored along 6 h (Table S2). Apathy, piloerection and 
squint-eyes were developed following toxin treatment, alone or 
in combination with PYY(3–36) [PYY(3–36)-OA]. Both OA 
and PYY(3–36)-OA-treated mice still presented symptoms at 
the end of the experiment.
Subsequently, the balance of body weight (Fig. S2a), food 
(Fig. S2b) and water consumption (Fig. S2c) were measured. 
Anatomopathological evaluation revealed swollen stomachs 
and small intestine fluid accumulation of the toxin-treated ani-
mals, with or without PYY(3–36) (Fig. S2d).
Diarrhoea score shows no differences between OA and 
PYY(3–36)-OA (Fig. 3a). Diarrhoea outbreak of PYY(3–36)-
OA-treated mice displays a slight time delay when compared 
to OA alone [OA 43 ± 7.8 min; PYY(3–36)-OA 49 ± 4.2 min] 
(Fig. 3b). Still, it is a remarkable fact that 100% of OA-treated 
mice presented diarrhoea; meanwhile, 85.7% of PYY(3–36)-
OA-treated mice showed this symptom (Table S2 and Fig. 3a).
It was then of interest to analyse the effect of the toxin on 
PYY concentration (Fig. 3c, d). The amount of PYY meas-
ured in small intestine has a remarkable non-significant 
increase in PYY(3–36)-OA-treated mice (Fig. 3c). In the 
large intestine, PYY(3–36)-OA treatment induces a minor 
rise compared to control (Fig. 3d).
NPY and PYY(3–36) pre‑treatment effect on OA 
poisoning in 2 h experiments
Neither NPY nor PYY(3–36) modified OA poisoning, still 
it was of interest to assure that this was independent of OA 
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dose. Subsequently, 250 µg/kg OA was chosen to both assure 
diarrhoea (Fig. 1e–g) and avoid mortality (Table 2). Since 
diarrhoea outbreak appears in less than 2 h, this was set as 
the endpoint of the experiment. During this time, monitoring 
of clinical signs identified symptoms such as piloerection or 
squint-eyes in all treatments involving the toxin (Table S3).
Body weight variation (Fig. S3a) and food intake (Fig. 
S3b) were measured showing no significant differences 
between treatments. At the end of the experiment, mac-
roscopic evaluation of the abdominal cavity was per-
formed (Fig. S3c). Animals treated with OA, NPY-OA and 
PYY(3–36)-OA revealed fluid accumulation mainly along 
the intestine even some mice that had no stools. Large intes-
tines were also removed and examined separately (Fig. S3c). 
Diarrhoeic content was observed in OA-treated mice alone 
or in combination with NPY or PYY(3–36).
Diarrhoea was also evaluated (Fig. 4). The type of diar-
rhoea developed by animals pre-treated with either NPY or 
PYY(3–36) was not different from that induced by OA alone 
(Fig. 4a). Note that animals treated with control, NPY or 
PYY(3–36) had no stools during the experimental time, so 
the score is 0 (Fig. 4a) and no diarrhoea onset is shown 
for these treatments (Fig. 4b). Regarding onset time of 
diarrhoea, only a slight non-significant delay is observed 
in PYY(3–36) pre-treatment [OA 35 ± 2.1 min; NPY-OA 
38 ± 8.1 min; PYY(3–36)-OA 45 ± 5.5 min] (Fig. 4b).
CPH effect on OA poisoning
The lack of a robust reaction to Y receptor ligands led us to 
study secretory pathways instead of pro-absorptive mecha-
nisms. Serotonin is a key signalling molecule that medi-
ates physiological processes in the gut and its release is 
stimulated by diarrhoeagenic compounds. Cyproheptadine 
(CPH), an inverse agonist/antagonist of 5-HT receptors 1 
and 2, has been described to elicit a response at the level 
of other antisecretory drugs (Meddah et al. 2014). Conse-
quently, to assess the role of 5-HT on OA mechanism to 
induce diarrhoea, we administered 3 mg/kg CPH before OA 
treatment. The set of symptoms developed were observed 
for 6 h and were similar in mice that received OA and OA 
with CPH (CPH-OA) (Table S4). Diarrhoea was the repre-
sentative symptom and it should be highlighted that CPH 
pre-treatment reduced the prevalence from 100% of the toxin 
alone to 61.5% (Table S4 and Fig. 5a).
As in previous approaches, body weight variations (Fig. 
S4a) as well as food (Fig. S4b) and water intake (Fig. S4c) 
were measured. Food intake was reduced in groups of mice 
that received the toxin or CPH-OA (Fig. S4b). Macroscopic 
evaluation of the abdominal cavity revealed mild fluid accu-
mulation in the small intestine of animals that received OA, 
resembling that of CPH-OA treated mice (Fig. S4d). Large 
intestines were removed and examined (Fig. S4d). OA large 
intestines were featured by diarrhetic content; meanwhile, 
CPH pre-treatment helped nearly restore normal intestinal 
content.
With regard to diarrhoea measured parameters, no sig-
nificant difference in diarrhoea score was detected between 
OA and CPH-OA treated mice (Fig. 5a). Conversely, onset 
of diarrhoea is significantly delayed by CPH administration 
[OA 34 ± 3.7 min; CPH-OA 69.1 ± 3.2 min] (Fig. 5b). OA 
induced a stark increase in faeces wet weight that decreased 
significantly with CPH pre-treatment (Fig. 5c).
Intestine’s 5-HT was quantified in mice samples (Fig. 5d, 
e). OA and CPH-OA induced 5-HT increase in the small 
intestine (Fig. 5d). Although in large intestine, CPH-OA 
treatment shows a non-significant increase over the other 
treatments (Fig. 5e).
Dose–response of CPH in OA poisoning
The suppression of OA-triggered diarrhoea led us to perform 
a dose–response study. Since CPH effect occurs within 2 h 
after toxin administration, experimental time was reduced 
to 2 h. Here we assessed 0.1, 1, 3 and 10 mg/kg CPH as a 
pre-treatment for 250 µg/kg OA. Clinical signs developed 
by each group of treatment were monitored (Table S5). It is 
noteworthy that diarrhoea was present in all mice adminis-
tered with OA, but was absent in those pre-treated with 3 or 
10 mg/kg CPH.
Body weight variation (Fig. S5a) as well as food inges-
tion (Fig. S5b) were measured. It was observed a tendency 
in weight lost and reduced food intake. On the contrary, 
anatomopathological examination provides information 
regarding the gastrointestinal tract at macroscopic level 
(Fig. S5c). Fluid accumulation in the stomach and intestine 
was observed for OA-treated mice. In animals pre-treated 
with 0.1, 1 and 3 mg/kg CPH, OA still induced fluid accu-
mulation in the intestine and stomach. However, mice with 
10 mg/kg CPH pre-treatment displayed an ameliorated 
fluid content in the intestine and a degree of solid content 
Fig. 1  Dose–response for diarrhoea induced by doses from 10 to 
400 µg/kg okadaic acid in a 24 h study period. a Variation on mice 
body weight, food and water intake. b Representative images of the 
mice abdominal cavity at the end of the experiment. Image corre-
sponding to 400 µg/kg OA was taken 11:45 h after toxin administra-
tion, time at which the animal died. c Neuropeptide Y measured in 
small and large intestines. d Peptide YY detected in small and large 
intestines. e Diarrhoea score. f Diarrhoea onset time. Inner box line 
indicates median and dashed lines are set at 25 and 50 min. Graphs a, 
c, d and e display mean ± SEM (n = 3). Since no animal treated with 
400  µg/kg accomplished the experimental time, data for this dose 
are separated by dotted line. Statistical analysis was conducted with 
one-way ANOVA–Bonferroni multiple comparison test. In e, treat-
ments with ‘#’ over the bar are significantly different (P < 0.001) from 
those with a ‘ + ’. Significance is indicated with asterisks over the line 
between treatments, so that *P < 0.05, otherwise non-significant
◂
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in the stomach. Complementary, large intestine state was 
evaluated (Fig. S5c), diarrhetic content is appreciated in 
mice administered the toxin alone or in combination with 
0.1 mg/kg CPH. A mild improvement can be appreciated 
in the intestine of mice pre-treated with 1 mg/kg CPH, 
being back to normal with 3 and 10 mg/kg CPH.
In a further evaluation of diarrhoea, score and onset 
were studied (Fig. 6a, b). Diarrhoea score varies between 
2.7 and 4 (Fig. 6a). There was a delay in diarrhoea onset 
when mice were pre-treated with 0.1 or 1 mg/kg CPH 
(Fig. 6b). In opposite, 3 and 10 mg/kg CPH pre-treatment 
blocked OA-induced diarrhoea (Fig. 6a). It should be 
taken into consideration the fact that control mice, or mice 
treated with CPH or OA plus 3 or 10 mg/kg CPH had no 
stools along the experiment (Fig. 6b).
We examined if different doses of CPH had any effect 
on 5-HT concentration (Fig. 6c, d). Overall, no signifi-
cant variations were observed in small intestine’s 5-HT 
(Fig. 6c). In the large intestine, there was a dose-dependent 
no significant decrease in 5-HT (Fig. 6d).
Evaluation of CPH doses effect when OA induced 
diarrhoea
Based on the previous results, it was interesting to assess 
the effect of CPH when diarrhoea was triggered by OA. 
To elucidate this, first animals were pre-treated with dif-
ferent doses of CPH and 30 min later treated with 250 µg/
kg OA and euthanised at the time when diarrhoea should 
appear. Average of OA-triggered diarrhoea outbreak was 
33 ± 2.3 min (Fig. 7b); therefore, this time was set as the 
end of the experiment. Notice the fact that only OA-treated 
mice had diarrhoea as shown by diarrhoea score (Fig. 7a).
During the brief experimental time, symptoms developed 
were observed (Table S6). No mice treated with any dose of 
CPH plus OA developed diarrhoea.
Both mice body weight balance (Fig. S6a) and food con-
sumption (Fig. S6b) display subtle variations due to the 
shortened experimental time.
Determination of 5-HT in the small (Fig. 7c) and large 
intestine (Fig. 7d) was then conducted. OA increased 5-HT 
Fig. 2  NPY effect on OA-induced diarrhoea and changes in NPY 
in the gut at 6  h experiment. Animals were given 107  µg/kg NPY 
15  min prior to 550  µg/kg OA administration. a Diarrhoea score 
(bars) and percent of mice that developed diarrhoea (closed squares). 
b Time of diarrhoea outbreak, values are expressed as boxplot 
showing the median. c–d NPY concentration in small (c) and large 
intestines (d). Data are mean ± SEM (n = 4 performed in duplicate). 
Student t test resulted in no significant differences (b). For c and d, 
statistical analyses were performed by one-way ANOVA and Bonfer-
roni multiple comparison test with no significant differences
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in the small intestine (non-significant) that decreased 
with CPH pre-treatments (Fig. 7c). Conversely, the toxin 
induced a modest 5-HT rise not observed in the presence 
of 1 nor 6 mg/kg CPH in the large intestine (Fig. 7d).
Necroscopy of mice allowed the evaluation of the OA-
induced effects along the gastrointestinal tract (Fig. 7e). 
No clear differences between administration of OA alone 
or in combination with 0.1 or 1 mg/kg CPH were detected. 
Yet, pre-treatment with 6 mg/kg CPH did improve the gas-
trointestinal tract aspect bringing it closer to that of con-
trol. In the large intestine, diarrhetic content was noticed 
in mice treated with OA and OA plus 0.1 mg/kg CPH, 
which was partially reversed by 1 mg/kg CPH (Fig. 7e). 
As described for the small intestine, 6 mg/kg CPH large 
intestines resembled those of control.
Discussion
Microalgae of the genera Dinophysis and Prorocentrum 
produce OA and form hazardous blooms leading to adverse 
environmental consequences associated with the declines 
of zooplankton populations (Gong et al. 2021). Besides, the 
consumption of seafood contaminated by OA or their struc-
tural derivatives, dinophysis toxins, causes DSP (Yasumoto 
et al. 1978). Due to the human health concerns associated 
Fig. 3  PYY(3–36) effect on OA-induced diarrhoea and changes 
in PYY in the gut at 6 h. PYY(3–36) (1 mg/kg) was given to mice 
15 min previous to OA (550 µg/kg). a Diarrhoea score (bars) along 
with percent of mice with diarrhoea (closed squares). b Time of diar-
rhoea onset; median is shown within each box. c–d PYY detected in 
small (c) and large (d) intestine of mice 6  h after treatments. Data 
are presented as mean ± SEM (n = 3 performed in duplicate). Student 
t test (b) or one-way ANOVA (a, c and d) were performed with no 
statistical significance detected in either case
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with DSP, OA group of phycotoxins are tightly regulated 
by European Union legislation (Union 2011). Even though 
many in vitro and in vivo studies have been performed with 
OA, there are still many gaps about the targets involved in its 
acute oral toxicity (Louzao et al. 2021; Huguet et al. 2020; 
Dietrich et al. 2019; Reale et al. 2019; Tripuraneni et al. 
1997; Ferron et al. 2014; Vilarino et al. 2018). It is stated in 
the literature that okadaic acid group of toxins are inhibitors 
of Ser/Thr protein phosphatases 1 (PP1) and 2A (PP2A) 
which play many roles in the cell (Takai et al. 1992). How-
ever, some challenging reports arise the possibility of differ-
ent action mechanisms triggering gastrointestinal symptoms 
(Vilarino et al. 2008; Espina et al. 2010; Munday 2013). 
However, taking into account the rapid onset of this main 
symptom, the involvement of the enteric nervous system 
should not be ruled out. Thus, it is of great interest to eluci-
date the specific signalling pathway resulting in OA-induced 
diarrhoea.
We designed an OA dose–response study to character-
ize, among others, effects caused by the toxin for 24 h and 
particularly diarrhoea onset. In some mice, OA induced 
various symptoms such as on hind legs, squint-eyes, apathy, 
piloerection or spasms, but all animals that showed clinical 
signs of intoxication developed diarrhoea. The toxic effects 
of OA included fluid accumulation in the gastrointestinal 
tract, and even death at high doses. To perform a risk assess-
ment, parameters as No-Observed-Adverse-Effect-Level 
(NOAEL) derived from the estimated exposures have been 
used to define Acute reference dose (ARfD) for humans. 
In our hands, 50 µg/kg OA was the highest administered 
dose at which no symptom or clinical sign was observed. 
This NOAEL agrees with the one proposed by EFSA in 
mice (2008). Besides our study revealed that 100 µg/kg OA 
was the lowest dose developing symptoms according to the 
LOAEL (Lowest-Observed-Adverse-Effect-Level) previ-
ously indicated in humans (Toyofuku 2006). Administra-
tion of doses equal or higher than 100 µg/kg OA triggers 
diarrhoea reaching the score of 3 or 4, with no differences 
in time onset indicating an all-or-none response. This could 
suggest a neuronal pathway in OA pathophysiology as 
was previously published in relation to the intestine water 
absorption-secretion balance (Delbro and Lange 1997). 
Recently, OA has also been involved in oxidative stress and 
inflammation pathways activation in enteric glial cell culture 
(Reale et al. 2019).
Diarrhoea represents an increase in water content of the 
stool and in the frequency of evacuation and mainly results 
from dysregulation of either intestinal secretory function or 
colonic motor function (Moriya et al. 2010). These intestinal 
activities are regulated by the enteric nervous system and 
implicate the Neuropeptide Y family as mediators (Vona-
Davis and McFadden 2007). This family includes Neuropep-
tide Y (NPY) and Peptide YY (PYY) that act as hormone 
and/or neurotransmitters/neuromodulators. They exert their 
functions through binding to Y-receptor subtypes of trans-
membrane-domain G-protein-coupled receptors (El-Salhy 
et al. 2020). PYY and NPY have similar biological effects 
and bind to and activate receptors  Y1 and  Y2 localized in 
epithelial cells and submucosal and myenteric plexus neu-
rons of the small intestine and colon (Mao et al. 1996; Cox 
et al. 2001; Wang et al. 2010). They delay gastric emptying 
and are mediators of the ileal break, also inhibit gastric and 
pancreatic secretion and stimulate the absorption of water 
and electrolytes. In some ways, they provide an integrated 
functional defence against luminal harmful factors includ-
ing toxins.
Some diarrhetic agents have been proven to alter NPY 
and PYY expression (Moriya et al. 2010). Previous studies 
Fig. 4  NPY or PYY(3–36) pre-treatment effects on OA diarrhoea 
during 2  h experiments. NPY (107  µg/kg) or PYY(3–36) (1  mg/
kg) were administered 15 min prior to receiving OA (250 µg/kg). a 
Diarrhoea score (bars) and percent of mice that developed diarrhoea 
(closed circles). b Diarrhoea onset time, boxes show data distribution, 
indicating the median as the line within each box. Data are expressed 
as mean ± SEM (n = 3 with duplicates). One-way ANOVA was con-
ducted resulting in no significant differences in either case
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(Valdiglesias et al. 2012; Louzao et al. 2015) have also 
shown an impairment of NPY production on SH-SY5Y neu-
roblastoma cell line when treated with OA. In agreement 
with these results, in vivo, we found a decrease in small 
intestine NPY concentration mainly after 24 h of oral OA 
administration. This could be related to the increase in intes-
tinal fluid secretion observed in necropsy. Other diarrhoeic 
compounds, for example, Cholera toxin, induce hyperexcita-
bility of secretomotor neurons in enteric pathways (Gwynne 
et al. 2009), while intraarterial infusion of the neuropeptide 
notably reduced this enterotoxin-evoked fluid secretion in 
cats (Sjoqvist et al. 1988). However, pre-treatment with NPY 
did not reduce OA-induced diarrhoea and intestinal fluid 
accumulation was only modestly improved. This was further 
supported by similar results obtained at a shorter time of 
exposure and with lower OA dose.
PYY exerts multiple physiological effects on the gastro-
intestinal tract (El-Salhy et al. 2020). PYY inhibited Pros-
taglandin  E2  (PGE2) and Vasoactive Intestinal Peptide that 
stimulated intestinal water secretion in the human small 
intestine being a defence against diarrhoea (Moriya et al. 
2010; Roze et al. 1997). We detected a reduction in PYY 
in the small intestine of mice 24 h after receiving OA but 
this decrease was not clear after 6 h of treatment. Besides, 
 Y2 agonist PYY(3–36) administration had no effect on OA-
induced diarrhoea although it was previously reported that 
Fig. 5  CPH pre-treatment effect 
on OA-induced diarrhoea (6 h). 
Mice were treated with CPH 
(3 mg/kg) 30 min before OA 
(250 µg/kg) administration. a 
Diarrhoea score (bars) along 
with the percent of animals 
developing diarrhoea (closed 
circles). b Time of diarrhoea 
outbreak. Inside boxes median 
is indicated. c Faeces wet 
weight. d–e 5-HT concentra-
tion measured in small (d) and 
large intestines (e) of mice. 
Mean ± SEM (n = 7 of dupli-
cates) are presented. One-way 
ANOVA (a, c) or Kruskal–Wal-
lis (d–e) followed by Bonfer-
roni multiple comparison test 
was performed. Significance is 
indicated by asterisks over the 
line between groups, such as 
*P < 0.05. Student t test com-
paring OA with CPH-OA was 
conducted to study diarrhoea 
onset (b), resulting in *P < 0.05
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PYY prevented faecal pellet output caused by dimethyl-
PGE2 (Moriya et al. 2010) or inhibited propulsive colonic 
motor function through  Y2 receptor in conscious mice 
(Wang et al. 2010).
Therefore, the addition of Y receptor agonist NPY  (Y1 
and  Y2 receptors) or PYY(3–36)  (Y2 receptor) induced 
almost no improvement on intestinal and stomach fluid accu-
mulation even in mice that had no faeces. Besides, the lack 
of a robust delay or prevention of OA-induced diarrhoea by 
targeting pro-absorptive peptides suggests that other enteric 
nervous pathways should be involved.
Serotonin is an endogenous signalling molecule involved 
in the regulation of fluid and mucus secretion as well as 
regulation of ion transport in gastrointestinal tract (Ban-
skota et al. 2019) capable of altering intestinal motility 
and implicated in diarrhoea outcome (Thiagarajah et al. 
2015; Camilleri et al. 2017; Hu and Spencer 2018). In fact, 
several diarrhoeagenic agents have been strongly related 
to this molecule (Ha et al. 2021; Westerberg et al. 2018; 
Singhal et al. 2017). Serotonin effects are achieved through 
the action on epithelial 5-HT2 receptor and neuronal 5-HT1, 
5-HT3 and 5-HT4 receptors (Fidalgo et al. 2013). Cypro-
heptadine (CPH) a 5-HT1 and 5-HT2 receptor antagonist/
inverse agonist has potent antiserotoninergic effects decreas-
ing contraction of longitudinal smooth muscles of small 
intestine in mice (Fida et al. 2000). Our experiments are 
the first to evaluate the effects of 5-HT receptor antagonist 
during OA intoxication in vivo. In our CPH dose–response 
study at 2 h, the highest dose (10 mg/kg CPH) prevented 
the phycotoxin effects regarding diarrhoea, even lower 
doses (0.1 and 1 mg/kg CPH) delayed OA-induced diar-
rhoea onset. Average of OA-triggered diarrhoea outbreak 
was 33 ± 2.3 min. At this time, serotonin measured in large 
intestine was slightly elevated in OA-treated mice and 
Fig. 6  Dose-dependent effect of CPH on OA-induced diarrhoea 
(2  h). Mice received 0.1, 1, 3 or 10  mg/kg CPH 30  min before the 
administration of 250  µg/kg OA. a Diarrhoea score (bars) and per-
cent of mice developing diarrhoea (closed squares). b Time of diar-
rhoea onset; line within each box represents the median. c–d 5-HT 
concentration measured in small (c) and large (d) intestines. Data are 
shown as mean ± SEM (n = 3 of duplicates). One-way ANOVA (a–b) 
or Kruskal–Wallis (c–d) and Bonferroni multiple comparison tests 
were performed as statistical analyses. No significant differences were 
detected
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remains high in CPH pre-treated mice. Interestingly, our 
results showed no diarrhoea in mice pre-treated with CPH 
at any dose; meanwhile, OA-treated mice have this symptom 
30 min after receiving the toxin. Other potent diarrhoeagenic 
compounds, such as Cholera toxin, cause the symptom by 
increasing the secretion of water into intestinal lumen. It can 
modify gastrointestinal motility by stimulating secretomotor 
neurons leading to the release of serotonin from enteroen-
docrine cells (Spencer and Hu 2020). This enterotoxin has 
been reported to prompt hypersecretion via 5-HT release in 
Fig. 7  CPH pre-treatment effect on OA-induced diarrhoea onset. 
Mice were pre-treated with 0.1, 1 or 6 mg/kg CPH and 30 min later 
treated with 250 µg/kg OA. The end of the experiment was set at the 
time OA triggered diarrhoea. a Diarrhoea score (bars) and percent of 
mice having diarrhoea (closed diamonds). All animals had normal 
or no stools (score of 0), but for those treated with OA. b Time of 
diarrhoea onset presented as a boxplot indicating the median inside 
the box. c–d 5-HT concentration detected on small (c) and large 
(d) intestines of mice. e Representative images of abdominal cavity 
and large intestine. Mean ± SEM (n = 3 of duplicates) is presented. 
Kruskal–Wallis (c) or one-way ANOVA (d) resulted in no significant 
differences
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human (Bearcroft et al. 1996) and rat jejunum (Beubler et al. 
1989) as well as in vitro primary enterochromaffin tumour 
cells (Hagbom et al. 2011). In accordance, 5-HT2 and 5-HT3 
receptors have been described to mediate this toxin-induced 
fluid secretion in rat jejunum (Beubler et al. 1989; Beubler 
and Horina 1990) while the antagonist of 5-HT2 receptor 
ketanserin ameliorated fluid secretion evoked by the com-
pound in rats (Harville and Dreyfus 1995). Our results 
showed that an increase in fluid secretion occurs within 
30 min exposure of OA. This early secretion can be partially 
inhibited by CPH, making the contents of the large intestine 
normal (this was not achieved with pre-treatments with NPY 
or PYY), suggesting a role for serotonin as a mediator during 
this stage. In relation to this, it was reported that CPH has a 
direct effect on the inhibition of electrogenic ion secretion 
in the intestinal epithelium (Meddah et al. 2014). This effect 
could also explain the clear improvement of clinical signs 
and major gross findings of dilation of the large bowel appre-
ciated during necropsy in CPH pre-treated mice. Therefore, 
CPH inhibited the OA-induced diarrhoea by blocking sero-
tonin activity on 5-HT receptors. All these findings entail 
an indication of neuronal signalling mediation in the patho-
physiology of DSP in mice, mainly involving 5-HT activity.
Conclusions
The fast symptoms OA causes during shellfish poisoning 
in humans (diarrhoea, nausea, vomiting and abdominal 
pain) suggested a neurogenic component. We determined 
that diarrhoea onset is an all-or-none response independent 
from the given OA dose. Moreover, we showed the inhibi-
tory effect of cyproheptadine on OA-induced diarrhoea, 
involving serotonin in the toxicity mechanism. This work 
evidences OA effect mainly on serotonin action and leads 
to gain further insight into the mechanism triggering diar-
rhoea. Also, it opens the possibility to further research the 
OA effect in the enteric nervous system and the enteroen-
docrine cross-talk.
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